By Colin Kellaher
Regeneron Pharmaceuticals said the Food and Drug Administration has accepted for review its resubmitted application seeking approval of odronextamab for certain patients with one of the most-common subtypes of non-Hodgkin lymphoma.
Regeneron, which is seeking an FDA nod for odronextamab in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy, said the agency set a target action date of July 30 for a decision.
The FDA last year turned away Regeneron's initial odronextamab application due to issues related to the enrollment status of confirmatory trials.
The Tarrytown, N.Y., biotechnology company on Wednesday said the FDA's acceptance of its resubmission follows the achievement of an FDA-mandated enrollment target.
Regeneron last year won European Commission approval of odronextamab as Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 26, 2025 07:43 ET (12:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。